Prostate Cancer Clinical Trial
Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer
Summary
RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo followed by ultrasound-guided biopsy in finding prostate cancer.
PURPOSE: This randomized phase III trial is studying dutasteride and ultrasound-guided biopsy to see how well they find prostate cancer compared with a placebo and ultrasound-guided biopsy.
Full Description
OBJECTIVES:
Determine the efficacy of dutasteride followed by contrast-enhanced, ultrasound-guided targeted biopsy in detecting prostate cancer.
Determine the detection rate of prostate cancer with targeted biopsy using contrast-enhanced ultrasound combined with dutasteride.
Determine the efficacy of targeted biopsy using contrast-enhanced ultrasound vs systematic biopsy in diagnosing clinically significant prostate cancer.
Determine the reduction in post-biopsy bleeding after dutasteride in these patients.
Determine the cost effectiveness of this regimen in these patients.
OUTLINE: This is a prospective, double-blind, placebo-controlled, randomized study. Patients are randomized to 1 of 2 arms.
Arm I: Patients receive oral dutasteride once daily on days 1-14.
Arm II: Patients receive oral placebo once daily on days 1-14. On day 14, patients in both arms undergo blood collection and contrast-enhanced (perflutren protein-type A microspheres) transrectal ultrasound. Conventional gray-scale imaging, color Doppler imaging, and power Doppler imaging are performed. Biopsies are then performed; first up to 6 targeted ultrasound-guided biopsies and then up to 12 systematic biopsies.
After completion of study procedures, patients are followed at 1 day.
PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Suspected prostate cancer due to 1 of the following criteria:
Prior abnormal digital rectal exam
Elevated prostate-specific antigen (PSA) ≥ 2.6 ng/mL within the past 90 days
PSA velocity > 0.75 ng/mL/year
Must be planning to undergo a transrectal ultrasound with biopsy
PATIENT CHARACTERISTICS:
Must be in adequate physical health to tolerate a prolonged transrectal examination and biopsy
Must not be clinically unstable, severely ill, or moribund
PRIOR CONCURRENT THERAPY:
More than 30 days since prior biopsy of the prostate
More than 1 week since prior acetylsalicylic acid or blood thinner
More than 30 days since prior participation in a clinical trial involving an investigational drug
No prior therapy for prostate cancer
No other concurrent 5-alpha reductase inhibitor
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19107, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.